Cannabis Rescheduled in the USA

A major federal shift announced on December 18, 2025 — and what it could mean next.

On December 18th, 2025, the United States took one of its biggest federal steps on cannabis in decades: the government began the process to reschedule cannabis under U.S. drug law. It’s a headline that sounds technical — but the impact could be huge.

Rescheduling doesn’t mean cannabis is suddenly “legal everywhere” in America. What it does mean is this: the federal government is moving away from its harshest classification and toward a category that recognises medical use. That shift can change everything from research to taxes to the future of cannabis laws in the USA.

What does “rescheduling” actually mean?

In the U.S., drugs are organised into categories called schedules under the Controlled Substances Act. These schedules affect how substances are regulated, how research is approved, how enforcement works, and even how businesses are taxed.

For years, cannabis has sat in Schedule I — the strictest group. Schedule I is meant for substances the government claims have no accepted medical use and a high potential for abuse.

The rescheduling process now underway aims to move cannabis to Schedule III. Schedule III is still regulated, but it’s a category that recognises medical value and is treated very differently under federal rules.

In plain language: the federal government is shifting from “no medical use” to “medical use acknowledged.” That alone is historic.

Why this matters (even outside the USA)

This isn’t just a policy tweak — it’s a cultural moment. The United States has shaped global cannabis conversations for decades, from prohibition-era messaging to modern reform debates. When federal policy changes in the U.S., it can influence research funding, international discussions, investment trends, and how other countries approach reform.

For museum visitors and cannabis history fans, rescheduling is one of those rare events where you can watch cannabis history being rewritten in real time.

What could change if Schedule III moves forward?

1) Research could become easier and faster

Cannabis research in the U.S. has long been slowed down by strict federal red tape. Rescheduling can reduce barriers that make studies difficult to start, difficult to fund, and difficult to scale.

That could lead to better-quality research into areas people care about most — such as pain management, sleep, PTSD, neurological conditions, and other therapeutic uses.

2) Cannabis businesses could see major tax changes

One of the most talked-about effects is financial: U.S. cannabis companies have faced unusually harsh federal tax treatment for years due to rules tied to Schedule I substances.

If cannabis moves to Schedule III, many businesses could be treated more like “normal” companies for tax purposes, which could mean more money going into compliance, product safety, staff, innovation, and long-term stability.

3) The banking conversation could shift

Rescheduling does not instantly solve banking issues — but it can signal to financial institutions that federal policy is changing direction. Over time, this could support broader reforms that simplify payments, insurance, and lending for the legal cannabis industry.

What rescheduling does not do

This is the part many headlines skip. Rescheduling is important — but it does not automatically fix everything. Here’s what does not change overnight:

- - It does not fully legalise cannabis federally. Cannabis can still be restricted under federal law.
  - It does not override state laws. Each state still controls its own medical and adult-use rules.
  - It does not automatically clear past convictions. That requires separate legal action and policy changes.
  - It does not instantly open interstate cannabis trade. Shipping cannabis across state lines remains legally complex.

Bottom line: rescheduling opens doors, but it’s not the final destination.

Why cannabis history fans should pay attention

For more than 50 years, U.S. federal policy treated cannabis as if it had no value. At the same time, millions of people used it medically, states built regulated markets, and research slowly expanded despite restrictions.

This rescheduling move is a clear sign that the old story is changing — and once the federal government changes its official classification, it can create momentum for the next phase of reform.

Whether the future brings broader legalisation, deeper medical regulation, or new federal frameworks, one thing is clear: December 18th, 2025, will be remembered as a major milestone in U.S. cannabis policy.

At the Cannabis Museum, we don’t just preserve cannabis history — we track the moments when history shifts.

Quick FAQ

Is cannabis legal in the USA now?

No. Rescheduling is not the same as legalisation. U.S. cannabis laws still depend on both federal rules and state laws.

What is Schedule III?

Schedule III is a U.S. legal category for substances that are regulated but recognised as having medical use.

Will this change things immediately?

Some changes may take time. Rescheduling is a process, and many related issues (banking, criminal justice reform, interstate trade) require additional policy changes.